The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy. The post Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace appeared first on Bio… Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

The fields of chemistry and materials science are seeing a surge of interest in “self-driving labs,” which make use of artificial intelligence (AI) and automated systems to expedite research and discovery. Researchers are now proposing a suite of definitions and performance metrics that will allow researchers, non-experts, and future users to better understand both what these new technologies are doing and how each technology is performing in comparison to other self-driving labs. Self-driving labs hold tremendous promise for accelerating the discovery of new molecules, materials and manufacturing processes, with applications ranging from electronic devices to pharmaceuticals. While the technologies are still fairly new, some have been shown to reduce the time needed to identify new materials from months or years to days. https://www.nature.com/articles/s41467-024-45569-5